Literature DB >> 1994206

Towards the development of the ideal malaria vaccine. A decade of progress in a difficult field.

M F Good1.   

Abstract

Malaria remains one of the world's most serious diseases, affecting the lives of up to 500 million people. The rapid development of drug resistance enhances the need for the development of a vaccine. Since the first cloning of malaria proteins early in the last decade, there have been a number of "subunit" vaccine trials involving humans and monkeys. During this time, our understanding of the basic immunobiology of malaria has increased; different immune mechanisms are required to combat the different stages in the life cycle of the parasite, and the future vaccine will have to stimulate these different effector mechanisms. There has been steady progress over the last decade toward an effective vaccine, but a great deal of further effort is still required.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1994206

Source DB:  PubMed          Journal:  Med J Aust        ISSN: 0025-729X            Impact factor:   7.738


  2 in total

1.  Effect of hookworm infection and anthelmintic treatment on naturally acquired antibody responses against the GMZ2 malaria vaccine candidate and constituent antigens.

Authors:  Benjamin Amoani; Ben Gyan; Samuel Asamoah Sakyi; Emmanuel Kwasi Abu; Samuel Victor Nuvor; Precious Barnes; Tracy Sarkodie-Addo; Benjamin Ahenkorah; Christian Sewor; Duah Dwomoh; Michael Theisen; Michael Cappello; Michael D Wilson; Bright Adu
Journal:  BMC Infect Dis       Date:  2021-04-08       Impact factor: 3.090

2.  Cohort study of the association of antibody levels to AMA1, MSP119, MSP3 and GLURP with protection from clinical malaria in Ghanaian children.

Authors:  Daniel Dodoo; Anastasia Aikins; Kwadwo Asamoah Kusi; Helena Lamptey; Ed Remarque; Paul Milligan; Samuel Bosomprah; Roma Chilengi; Yaa Difie Osei; Bartholomew Dicky Akanmori; Michael Theisen
Journal:  Malar J       Date:  2008-07-29       Impact factor: 2.979

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.